The Escape Hatch That Medicare Wants to Slam Shut

The clinical pitch was real: patients get their treatment in minutes instead of half an hour, freeing up infusion chairs and making life easier. But the financial pitch was arguably even more compelling. A fresh FDA approval date could mean years of protection from government price cuts.

CMS Says: Nice Try

The proposed rule, which would take effect in 2029, flips the script. Under the new framework, CMS would treat subcutaneous reformulations as part of the same drug family as the original IV version. That means if IV Keytruda gets selected for negotiation, subcutaneous Keytruda QLEX gets dragged along for the ride.

No new clock. No escape hatch. Same negotiation, same maximum fair price.

CMS framed this as a matter of "program integrity," targeting what it called evergreening: the practice of launching slightly different versions of existing drugs to sidestep regulation. The agency is also going after fixed-combination products (drugs that add an extra ingredient to dodge negotiation), but the subcutaneous policy is the headline grabber.

The rule isn't final yet. Comments are due August 17, 2026, and CMS expects to finalize everything by fall 2026. But the direction of travel is unmistakable.

Wall Street Reaches for the Antacids

Analysts didn't waste time sounding the alarm. JPMorgan called the guidance "somewhat targeted" at subcutaneous Keytruda and Opdivo specifically. RBC's Trung Huynh highlighted increased "negotiation risk" for Merck and other large-cap pharma names. Goldman Sachs' Asad Haider noted that investors had previously assumed subcutaneous versions would sit safely outside Medicare's reach for years; that assumption is now crumbling.

Merck's stock slid after the proposal dropped.

The math is daunting. Keytruda alone generated roughly $31.7 billion in 2025 revenue, with consensus estimates projecting a peak around $33 to $34 billion by 2028. Merck had told investors it expected 30 to 40% of Keytruda patients to eventually switch to the subcutaneous version.

All of that revenue was supposed to enjoy years of pricing freedom. Under the proposed rule, it wouldn't.

The Biosimilar Wildcard

Here's where the plot thickens. Both Keytruda and Opdivo face a key patent expiry in late 2028, with biosimilars (cheaper copycat biologics) expected to launch around December of that year.

Under IRA rules, a drug can escape negotiation if a biosimilar has been on the market for at least nine months before the price-effective year. Biosimilars launching in December 2028 wouldn't hit that nine-month threshold before January 2029. So even with competition arriving, both drugs would still face at least one year of negotiated prices.

But there's a twist. CMS included a provision saying that if biosimilars create enough price competition for the IV version, the agency could "deselect" the drug from negotiation entirely. In that scenario, the subcutaneous version might get different treatment regarding the price ceiling.

Jefferies analyst Akash Tewari pointed out that timing of biosimilar entry could still allow the subcutaneous versions to dodge selection, similar to what happened with high-dose Eylea. Leerink's David Risinger emphasized the uncertainty: it all depends on exactly when biosimilars arrive and how fast they gain traction.

The bottom line from the Street? "Incrementally negative" but "highly uncertain." That's analyst-speak for "this is bad, but we're not sure how bad yet."

Why This Matters Beyond Two Drugs

Zoom out and the stakes get even bigger. This rule isn't really about Keytruda and Opdivo. It's about whether pharmaceutical companies can use reformulation as a pricing strategy across their entire portfolio.

J&J's Darzalex Faspro (subcutaneous Darzalex) faces similar questions. So does any future IV-to-subcutaneous switch. CMS is essentially telling the industry: changing the route of administration doesn't change the drug, and it won't change the negotiation timeline.

For patients, the subcutaneous versions are genuinely better. A two-minute shot beats a 30-minute infusion every time. Nobody disputes that. The question is whether "better for patients" should also mean "more expensive for Medicare," especially when the underlying molecule is the same.

CMS has drawn its line. Pharma has until August 17 to argue otherwise. And billions of dollars are hanging in the balance while both sides sharpen their pencils.

The tunnel might not be sealed yet. But the concrete is already being mixed.

Adaptive Biotech Is Breaking Up With Itself

Adaptive Biotechnologies is splitting its profitable cancer diagnostics business from its early-stage drug discovery platform into two separate companies. The move follows a growing industry trend of corporate breakups designed to let fundamentally different businesses attract the right investors.